A mutated CCR5 gene may have favorable prognostic implications in MS.
The authors investigated the association between Delta32CCR5, a mutated allele of the chemokine receptor CCR5, and disease progression in 256 patients with multiple sclerosis (MS). The mutated allele frequency in the study cohort was 7.4%, similar to that reported in the general Israeli population. Progression to disability was prolonged in Delta32CCR5 homozygotes and heterozygotes compared with MS patients with the CCR5 wild-type genotype (p < 0.005). Mutated CCR5 allele may be considered a favorable prognostic factor in MS.
Kantor
Rami
R
Division of Infectious Diseases, Sheba Medical Center, Tel-Hashomer, Israel.
Bakhanashvili
Mary
M
Achiron
Anat
A
D000328:Adult; D017668:Age of Onset; D000483:Alleles; D015331:Cohort Studies; D018450:Disease Progression; D005061:Europe, Eastern / Q000208:ethnology; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005858:Germany / Q000208:ethnology; D006801:Humans; D007557:Israel / Q000453:epidemiology; D007585:Jews / Q000235:genetics; D008297:Male; D009103:Multiple Sclerosis / Q000453:epidemiology / Q000208:ethnology / Q000235:genetics*; D011174:Portugal / Q000208:ethnology; D011379:Prognosis; D019713:Receptors, CCR5 / Q000737:chemistry / Q000235:genetics*; D017384:Sequence Deletion; D016037:Single-Blind Method; D013030:Spain / Q000208:ethnology
D019713:Receptors, CCR5